Medical Device News Magazine

Wednesday, March 22, 2023

Dr. Matthew Thompson Named President/CEO of Endologix

Dr. Matthew Thompson, has been appointed as the new President and Chief Executive Officer of Endologix.

Dr. Matthew Thompson will also join Endologix’s Board of Directors. Richard Mott, who previously held the CEO position on an interim basis, will return to his role as Executive Chairman of the Board of Directors.

Dr. Thompson has been serving as Endologix’s Chief Medical Officer since 2016, and, in that capacity, had oversight of the Company’s business development, medical affairs, regulatory, clinical, and R&D departments. Dr. Thompson also led the April 2021 acquisition and subsequent integration of PQ Bypass. He is a contract Staff Surgeon, Department of Vascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation Ohio, and Visiting Professor Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Previously he was the Professor of Vascular Surgery at St George’s, University of London and a Consultant Vascular Surgeon at St George’s Vascular Institute.

“I have had the pleasure of working side by side with Matt over the past year and have the utmost confidence in his ability to lead Endologix through this transformative period. Matt embodies the fusion of the entrepreneurial vision and subject matter expertise that we need to successfully accelerate Endologix as a leader in the development and commercialization of the most innovative devices for the treatment of vascular disease,” said Richard Mott.

“I have been extremely impressed with Matt’s leadership of major company initiatives, including the PQ Bypass acquisition and integration, and the AFX FDA advisory panel meeting, as well as his leadership of major functions within the Company,” noted Andrew El Bardissi, Deerfield partner and member of the Endologix Board of Directors. “I am confident in Matt’s ability to step into the CEO role and guide the company during this important period of growth.”

“I am excited about the opportunity to lead such a dynamic and innovative organization. I look forward to continuing my close relationship with Rich, the Board, and the talented and dedicated team of employees that I have worked so closely with over the past several years,” said Dr. Thompson. “I will be completely committed to our physician customers and to the safety and health of their patients, as we continue to work collaboratively with the US Food & Drug Administration (FDA) and other global regulatory agencies to ensure we maintain the highest standards possible. In the next year, we will continue to drive market share gains with our family of AAA products and prepare our regulatory submissions for our innovative long-lesion PAD products being developed after our acquisition of PQ Bypass earlier this year.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

U.S. Department of Defense Awards Theradaptive $4 Million Contract for Its OsteoAdapt Regenerative Therapeutic Program

The funds from the DOD contract will enable Theradaptive to continue its work to meet regulatory requirements and scale up Good Manufacturing Practices-compliant manufacturing of the OsteoAdapt product in preparation for clinical studies.

Macrolux Completes Nearly CNY100 million Series A Round: Funding Led by Legend Capital

Legend Capital has long been paying attention to the investment in the field of medical devices and diagnostics with a focus on three major themes: first, major diseases, especially the unmet clinical needs of chronic diseases; second, the first and uniqueness in technology, which enables a company to become or have the potential to become a leading player in subdivided industries; the third is the "device +" investment opportunities brought by the integration of medical devices and interdisciplinary technologies such as AI, IoT and Big Data.

Previa Medical Raises €2.1 Mil for AI Solution to Prevent Sepsis

Sepsis is one of the leading causes of hospital deaths worldwide, with a 30-day mortality rate of 20 to 30%. SEPSI-SCORE therefore provides a much-needed solution to a major global public health issue.
Subscribe to Medical Device News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy